TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Clear clinical and laboratory diagnosis of HAE~* Plasma level of functional C1INH of less than 50% of normal~* Acute abdominal, urogenital, peripheral, and/or oro-facial/pharyngeal/laryngeal HAE attack~Main Exclusion Criteria:~* Acquired angioedema~* Pregnancy or breastfeeding~* Treatment with any investigational drug within prior 30 days~* Body weight \>120 kg

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 100 IU/kg rhC1INH (Type: EXPERIMENTAL): 100 IU/kg Recombinant human C1 inhibitor
- 50 IU/kg rhC1INH (Type: EXPERIMENTAL): 50 IU/kg Recombinant human C1 inhibitor
- Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Skills Training for Adolescents With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 14 and 18~* In high school~* Principal Diagnosis of ADHD~* Stable prescription of Medications for ADHD~* ADHD has childhood onset~* Clinically significant ADHD symptoms~Exclusion Criteria:~* Organic Mental Disorders~* Active Substance Abuse or Dependence~* Diagnosis of Conduct Disorder~* Mental Retardation or Pervasive Developmental Disorder~* Active Suicidality~* Previous History of CBT Therapy in adolescence~* Other condition interfering with consent or participation

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- CBT for ADHD first, then follow-up (Type: EXPERIMENTAL): Participants received Cognitive Behavioral Therapy following randomization.
- Wait list first, then CBT for ADHD (Type: NO_INTERVENTION): Cross-over: Participants were assigned to a wait list after the initial assessment. They received Cognitive Behavioral Therapy after the 4 month assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Curcumin Gel Combined With Non-surgical Periodontal Therapy on Salivary Procalcitonin Level in the Treatment of Periodontitis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* inclusion criteria were participants of both sexes, between the ages of thirty and fifty -five years old with periodontitis (stage II grade A).~Exclusion Criteria:~* exclusion criteria involved participants with known systemic diseases, pregnant and lactating patients, tobacco users (smoking /chewing), history of antibiotic and periodontal therapy in the last three months, and participants who weren't compliant with oral hygiene procedures.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Study group (Type: OTHER): Study group treated with curcumin gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has symptoms of Overactive Bladder (OAB) (frequency and urgency) with Urge Urinary Incontinence (UUI) for a period of at least 6 months prior to screening.~* Participant experiences ≥ 1 episode of UUI per day.~* Participant has not been adequately managed with ≥ 1 oral or transdermal pharmacologic therapies for the treatment of their OAB symptoms.~Exclusion Criteria:~* Participant has symptoms of OAB due to any known neurological reason (e.g., spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).~* Participant has a predominance of stress incontinence in the opinion of the investigator, determined by participant history.~* Participant currently uses or plans to use medications or therapies to treat symptoms of OAB, including nocturia.~* Participants who have previously been treated with onabotulinumtoxinA for urological indications within 12 months of starting the Screening Bladder Diary, or any other toxin for urological indications, regardless of when treated (participants treated with onabotulinumtoxinA or other toxins for non-urological indications are eligible, regardless of when treated)

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: URO-902 24 mg; Placebo (Type: EXPERIMENTAL): Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
- Cohort 2: URO-902 48 mg; Placebo (Type: EXPERIMENTAL): Participants will receive either a single treatment of URO-902 48 mg or matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of SDF in Arresting Dental Caries in Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~The children included in the study should~1. aged 3-4 years who have tooth decay and are attending the first year of kindergarten,~2. be generally healthy,~3. have parental consent, and~4. have at least 1 tooth with untreated caries that extends into the dentine.~Exclusion Criteria:~* Children who are uncooperative and difficult to manage, have major systemic diseases, or are on long-term medication will be excluded.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- 38% SDF semi-annual (Type: EXPERIMENTAL): semi-annual application of 38% SDF
- 38% SDF annual (Type: EXPERIMENTAL): annual application of 38% SDF
- 12% SDF semi-annual (Type: ACTIVE_COMPARATOR): semi-annual application of 12% SDF
- 12% SDF annual (Type: ACTIVE_COMPARATOR): annual application of 12% SDF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Topical Administration of Common Drugs on Postoperative Bleeding and Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing unilateral simple mastectomy~* patients undergoing bilateral symmetric breast surgery~Exclusion Criteria:~* pregnancy~* A history of former thromboembolic events (to receive TXA)~* cardiovascular disease (to receive adrenaline)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- topical tranexamic acid (Type: EXPERIMENTAL): tranexamic acid to be smeared on surgical wounds before closure
- topical adrenaline (Type: EXPERIMENTAL): adrenaline solution to be smeared on surgical wounds before closure
- topical bupivacaine (Type: EXPERIMENTAL): bupivacaine to be smeared on surgical wounds before closure
- topical adrenaline plus tranexamic acid (Type: EXPERIMENTAL): tranexamic acid and adrenaline to be smeared on surgical wounds before closure
- placebo control (Type: PLACEBO_COMPARATOR): saline to be smeared on surgical wounds before closure
- tranexamic acid and placebo control (Type: PLACEBO_COMPARATOR): tranexamic acid and saline to be smeared on surgical wounds before closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-muscle invasive transitional cell carcinoma (TCC) of the bladder (Ta, T1, Tis) recurrent after initial surgery and at least one round of adjuvant treatment (i.e. 6 weeks of intravesical biological therapy with Bacillus Calmette Guerin (BCG) solution); or~* An inability to tolerate BCG~* Age \> 18~* Eastern Cooperative Oncology Group(ECOG) Performance Status 0-2~* Laboratory tests performed within 14 days of study enrollment:~  * Leukocytes ≥ 3,200, Absolute Neutrophil count ≥ 1,500, Platelets ≥ 100,000~ * Hemoglobin ≥ 9.0 gm/dL, Total bilirubin ≤ institution upper limit of normal \*(ULN), Asparate Aminotransferase(AST) and Alanine Aminotransferase(ALT) ≤ 2.5 times ULN, Alkaline phosphatase ≤ 2.5 times ULN~ * Creatinine ≤ 1.5 times ULN~* Women of child bearing potential must have a negative pregnancy test~* If post-menopausal - Amenorrhea for ≥ 12 months~Exclusion Criteria:~* Pregnancy or breastfeeding~* Muscle invasive disease (T2-T4)~* Prior radiation to the pelvis~* Peripheral neuropathy (any grade)~* Thrombocytopenia, coagulation disorder or an increase in bleeding tendency due to other causes~* Known bladder fistula~* Hypersensitive or idiosyncratic reaction to mitomycin-C or its components in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Hyperthermia system, Mitomycin C (Type: EXPERIMENTAL): Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a histologic or cytologic diagnosis of carcinoma of the gastroesophageal junction or esophagus;~* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria;~* Overexpression of EGFR defined by immunohistochemistry (3+) or gene amplification by fluorescence in-situ hybridisation;~* Have progressed after one chemotherapy regimen;~* Age 18-75 years old with performance status of 0 to 2~Exclusion Criteria:~* Prior targeted therapy with erlotinib, gefitinib, and so on~* Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).~* Known severe hypersensitivity to icotinib or any of the excipients of this product.~* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib (Type: EXPERIMENTAL): Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women (≥ 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.~* Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer~* Postmenopausal women.~* Disease refractory to non steroidal aromatase inhibitors (NSAI),~* Radiological or clinical evidence of recurrence or progression on or after the last systemic therapy prior to randomization.~* Patients must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease as defined above.~Exclusion Criteria:~* HER2-overexpressing patients~* Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites etc.).~* Patients who received more than one chemotherapy line for Advanced Breast Cancer.~* Previous treatment with exemestane or mTOR inhibitors.~* Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).~* Radiotherapy within four weeks prior to randomization~* Currently receiving hormone replacement therapy,~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus + Exemestane (Type: EXPERIMENTAL): Everolimus 10 mg daily in combination with exemestane 25 mg daily
- Placebo + Exemestane (Type: ACTIVE_COMPARATOR): Placebo of everolimus in combination with exemestane 25 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biological Effects of Dehydroepiandrosterone (DHEA) in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy women and men~* Age 60 or older~* Age-appropriate DHEAS levels, but 70% lower than normal DHEAS levels for a 25-year old~Exclusion Criteria:~* Contraindications to DHEA treatment (personal history of breast cancer or other estrogen-dependent neoplasms, acute liver disease, undiagnosed vaginal bleeding in women, history or evidence of prostate cancer or benign prostatic hyperplasia (BPH) in men)~* Angina~* Resting blood pressure over 180/95~* Chronic infections~* Hypothyroidism~* Depression~* Hormone therapy within the previous 6 months~* Insulin-dependent or poorly controlled diabetes~* Serum DHEAS level greater than 140 micrograms per deciliter (µg/dL)~Prohibited Medications:~* Hormone therapy other than stable regimen of thyroid replacement~* Oral glucocorticoids~* Insulin

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥ 18 years of old.~2. Clinical diagnosis of type 1 diabetes for at least one year.~3. The subject will have been on insulin pump therapy for at least 3 months.~4. Last (less than 3 months) HbA1c ≤ 12%.~Exclusion Criteria:~1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.~2. Recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.~3. Use of medication with an effect on heart rate (e.g. beta-blockers).~4. Abnormal blood panel and/or anemia.~5. Ongoing or planned pregnancy.~6. Severe hypoglycemic episode within two weeks of screening.~7. Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation).~8. Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc).~9. Problems with venous access.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Unannounced exercise (Type: ACTIVE_COMPARATOR): The target blood glucose of the algorithm will be as usual. A pre-meal full insulin bolus will be given.
- Announced exercise with pre-meal full bolus (Type: ACTIVE_COMPARATOR): The target blood glucose of the algorithm will be increased and a pre-meal full bolus will be given
- Announced exercise with reduced insulin bolus (Type: ACTIVE_COMPARATOR): The target blood glucose of the algorithm will be increased and the pre-meal insulin bolus will be reduced by 33%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 years of age or older.~* Need for an operative restorative dental procedure requiring local anesthesia for a single vital maxillary tooth (other than a maxillary first, second, or third molar) with no evidence of pulpal pathology.~* Normal lip, nose, eyelid, and cheek sensation.~* Able to understand and sign the study informed consent document, communicate with the investigators, and understand and comply with the requirements of the protocol.~* Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure.~* Resting heart rate (HR) between 55 and 100 beats per minute (bpm), inclusive.~* Seated systolic blood pressure (SBP) between 95 and 140 mm Hg, inclusive and seated diastolic blood pressure (DBP) between 60 and 90 mm Hg, inclusive.~Exclusion Criteria:~* Inadequately controlled hypertension (blood pressure greater than 140/90 mm Hg).~* Inadequately controlled active thyroid disease of any type.~* Frequent nose bleeds (≥ 5 per month).~* Having received dental care requiring a local anesthetic within the last 24 hours.~* History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).~* History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or sulfite preservatives.~* Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.~* Nursing, pregnant, suspected of being pregnant, or trying to become pregnant. (Females of child-bearing potential will be required to take a urine pregnancy test on the day of, but prior to, study drug administration to rule out pregnancy.)~* Having received any investigational drug and/or participation in any clinical trial within 30 days prior to study participation.~* Having used oxymetazoline or phenylephrine nasal spray, nasal irrigation, or other nasal or oral decongestant on the day of the study procedure.~* History of congenital or idiopathic methemoglobinemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Kovacaine Mist, 3 sprays unilateral (Type: EXPERIMENTAL): Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
- Tetracaine Only, 3 sprays unilateral (Type: EXPERIMENTAL): Tetracaine HCl 3%
- Placebo, 3 sprays unilateral (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 20 - 75 years old~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients whose HbA1c is between 6.5% and 10.0%~* Patients who took Thiazolidinedione for diabetes over 16 weeks before administration of investigational drug~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.~Exclusion Criteria:~* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)~* Patients who are accepting treatments of arrhythmias~* Patients with serious diabetic complications~* Patients who are the excessive alcohol addicts~* Patients with severe hepatic disorder or severe renal disorder.~* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo / Teneli + Pio (Type: PLACEBO_COMPARATOR): None
- Teneli / Teneli + pio (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete